A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
Study sponsor: Oncolytics Biotech
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-08-01Actual
Enrollment · participants48Actual
Source updated2025-01-16Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.